CD274 and non-small cell lung carcinoma: Since 2012, clinical studies have confirmed that immune checkpoint inhibitors (ICIs) with programmed death-1 (PD-1) or its ligand [programmed cell death-ligand 1 (PD-L1)] blockade can significantly prolong the survival time compared to traditional therapies in NSCLC (3–7).